Drugs / ST-0529
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03844932 | Jan 2019 → Apr 2021 | ulcerative colitis | Sublimity Therapeutics Holdco Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST-0529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03844932 ↗ |
| Route | Oral | “ST-0529: 18.75 mg orally twice daily (BID)” NCT03844932 ↗ |